Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 21 of the 23 sources its claims cite were checked for support.

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Open access

Abstract

The SARS-CoV-2 B.1.617 lineage was identified in October 2020 in India 1-5. Since then, it has become dominant in some regions of India and in the UK, and has spread to many other countries 6. The lineage includes three main subtypes (B1.617.1, B.1.617.2 and B.1.617.3), which contain diverse mutations in the N-terminal domain (NTD) and the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein that may increase the immune evasion potential of these variants. B.1.617.2-also termed the Delta variant-is believed to spread faster than other variants. Here we isolated an infectious strain of the Delta variant from an individual with COVID-19 who had returned to France from India. We examined the sensitivity of this strain to monoclonal antibodies and to antibodies present in sera from individuals who had recovered from COVID-19 (hereafter referred to as convalescent individuals) or who had received a COVID-19 vaccine, and then compared this strain with other strains of SARS-CoV-2. The Delta variant was resistant to neutralization by some anti-NTD and anti-RBD monoclonal antibodies, including bamlanivimab, and these antibodies showed impaired binding to the spike protein. Sera collected from convalescent individuals up to 12 months after the onset of symptoms were fourfold less potent against the Delta variant relative to the Alpha variant (B.1.1.7). Sera from individuals who had received one dose of the Pfizer or the AstraZeneca vaccine had a barely discernible inhibitory effect on the Delta variant. Administration of two doses of the vaccine generated a neutralizing response in 95% of individuals, with titres three- to fivefold lower against the Delta variant than against the Alpha variant. Thus, the spread of the Delta variant is associated with an escape from antibodies that target non-RBD and RBD epitopes of the spike protein.

Overview

CoChat Summary

## TL;DR

This study isolates an infectious SARS-CoV-2 Delta (B.1.617.2) virus and shows that it is less sensitive to neutralization by some monoclonal antibodies and by sera from convalescent or vaccinated individuals. Two vaccine doses restored strong neutralization, but Delta remained about 3- to 5-fold less sensitive than Alpha to vaccine-induced antibodies.

## Key findings

  • The Delta isolate contained eight spike mutations relative to D614G: T19R, G142D, Δ156-157, R158G, L452R, T478K, P681R, and D950N.
  • Among therapeutic monoclonal antibodies, bamlanivimab lost activity against Delta, while etesevimab, casirivimab, and imdevimab remained active; Delta was also resistant to some anti-RBD and anti-NTD antibodies.
  • In convalescent sera, Delta neutralization was fourfold lower than Alpha at month 12 in the Strasbourg cohort, and in the Orléans cohort Delta titers were four- to sixfold lower than Alpha and D614G, respectively.
  • After vaccination, a single dose gave weak neutralization: only 13% of Pfizer sera neutralized Delta after one dose, and only 4% and 9% of AstraZeneca sera neutralized Beta and Delta, respectively; after two doses, neutralizing responses rose to 95–100% of individuals for the tested strains.

## Methods

  • The authors isolated an infectious Delta variant from a nasopharyngeal swab of a symptomatic traveler returning from India, amplified it on Vero E6 cells, and compared it with D614G, Alpha, and Beta viruses.
  • They tested monoclonal antibodies and sera from human cohorts: 56 convalescent individuals from Orléans, 47 convalescent individuals from Strasbourg at month 12, and 59 vaccinated individuals (16 Pfizer, 43 AstraZeneca), using the S-Fuse neutralization assay and flow cytometry binding assays.
  • Main analyses included ED50/IC50 neutralization comparisons and group tests reported as Friedman with Dunn’s multiple comparisons and Kruskal-Wallis with Dunn’s multiple comparisons.

## Limitations

  • The paper explicitly states a low number of vaccinated individuals analyzed and no characterization of cellular immunity.
  • The study also states that the work is observational/exploratory, with no randomization and no blinding; this is a design limitation evident from the Methods and reporting summary.
  • Sample-size planning was not performed a priori: the paper says no statistical methods were used to predetermine sample size.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41586-021-03777-9

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

17 Valid · 1 Not valid · 2 Not checked · 80 Own results and interpretations

39 more claims · 2 with their cited sources checked

Create a free account to see all 100 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 34
  • Probably not a substantial claim. 31
  • The quote only partly states this claim. 7

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

8 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 38 references

Cited by

See all 2,019

Metadata

Authors
Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., Prot, M., Gallais, F., Gantner, P., Velay, A., Le Guen, J., Kassis-Chikhani, N., Edriss, D., Belec, L., Seve, A., Courtellemont, L., Péré, H., Hocqueloux, L., Fafi-Kremer, S., Prazuck, T., Mouquet, H., Bruel, T., Simon-Lorière, E., Rey, F. A., & Schwartz, O.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • Inserm (FR)
  • Institut Pasteur (FR)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • Centre hospitalier universitaire d'Orléans (FR)
Corresponding author
  • Bruel, Timothée
  • Schwartz, Olivier
Venue
Nature
Published
2021-07-08
Volume
596
Issue
7871
Pages
276-280
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W3182094313
Cited by
1,992
References
38
Citations by year
2026: 43 · 2025: 91 · 2024: 156 · 2023: 315 · 2022: 935 · 2021: 449
FWCI
146.93
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
  • Agence Nationale de la Recherche (PROTEO-SARS-CoV-2, ANR-10–INSB–04, ANR-10-LABX-77, 2017-, 10-LABX-62-IBEID, ANR-11-LABX-0070, ANR-10–INSB–04-01, 10-INSB-04-01, ANR‐10‐LABX‐62‐IBEID, ANR‐10‐LABX‐69‐01, LABX-62-IBEID, ANR-21-CO14-0007, DIM1Health, 10‐LABX‐69‐01, ANR18, ANR-10-LABX-0069, UMR_S 1109, ANR-10-LABX-0077, ANR-10, ANR-10-LABX, ANR-18-CE17-0028, ANR-10-LABX-0062, ANR-10-INBS-0004, ANR-10-LABX-62)
  • Institut National de la Santé et de la Recherche Médicale (UMR_S 1109, ANR-10-INSB-04-01, ANR-10-LABX-77, ANR-10-LABX-62-IBEID)
  • Fondation pour la Recherche Médicale (ANR-10-LABX-62-IBEID, PROTEO-SARS-CoV-2, ANR-10-LABX-77)
  • Conseil Régional, Île-de-France (DIM 1Health)
  • Fondation de France (#00106077)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Keywords
Delta variant, B.1.617, antibody neutralization, immune evasion, receptor binding domain, monoclonal antibodies, bamlanivimab, convalescent sera, COVID-19 vaccines, Alpha variant, spike protein mutations
MeSH terms
COVID-19, COVID-19 Vaccines, Antibodies, Viral, Epitopes, Convalescence, France, Humans, India, Male, Middle Aged, Neutralization Tests, Immune Evasion, Antibodies, Neutralizing, Antibodies, Monoclonal, Humanized, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. https://app.cochat.ai/papers/10.1038/s41586-021-03777-9
The paper
Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., Prot, M., Gallais, F., Gantner, P., Velay, A., Le Guen, J., Kassis-Chikhani, N., Edriss, D., Belec, L., Seve, A., . . . Schwartz, O. (2021). Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. https://doi.org/10.1038/s41586-021-03777-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.